Evidence map›Paper›PMID 15782116›Full record

ArticleOncogene2005

Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours.

Michael Scott, Paula L Hyland, Gordon McGregor, Kenneth J Hillan, S E Hilary Russell, Peter A Hall

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06778317 (Evaluation of the Circulating Epigenetic Biomarker mSEPT9 for Predicting the Occurrence of Hepatocellular Carcinoma in Patients With Cirrhosis), which is not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06778317 recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of the Circulating Epigenetic Biomarker mSEPT9 for Predicting the Occurrence of Hepatocellular Carcinoma in Patients With Cirrhosis: A Prospective Multicenter Trial (SEPT9_SuRV)

TypeobservationalSponsorCentral Hospital, Nancy, FranceRan2025 to 2033Enrolled400ConditionsHepatocellular Carcinoma (HCC), Cirrhosis, Risk Prediction for Liver Cancer, EpigenomicsArmsCirculating mSEPT9 Biomarker Testing
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Pilot Study by Liquid Biopsy in Gastrointestinal Stromal Tumors: Analysis ofInternational journal of molecular sciences · 2024
    Article
  6. Review
  7. Article
  8. Septins, a cytoskeletal protein family, with emerging role in striated muscle.Journal of muscle research and cell motility · 2021
    Review
  9. Structure and function of Septin 9 and its role in human malignant tumors.World journal of gastrointestinal oncology · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Acute myeloid leukemia withSAGE open medical case reports · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Michael ScottCentre for Cancer Research and Cell Biology, Queen's University Belfast, University Floor, Tower Block, Belfast City Hospital, Belfast BT9 7AB, UK.
Paula L Hyland
Gordon McGregor
Kenneth J Hillan
S E Hilary Russell
Peter A Hall
Queen's University Belfast · GBUniversity of Ulster · GBBelfast City Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Septins are an evolutionarily conserved family of GTPases with diverse functions including roles in cytokinesis that have been implicated in neoplasia. To address the potential role of SEPT9 in tumorigenesis, we assessed the expression of SEPT9 in 7287 fresh frozen human tissue samples and 292 human cell lines by microarray analysis. In addition, we used a sensitive RT-PCR strategy to define the expression of SEPT9 isoforms in archival formalin-fixed and paraffin-embedded normal human tissues. The mRNA data were further confirmed by immunohistological analyses of SEPT9 protein expression in normal human tissues using antisera that detect SEPT9 isoforms. Using these complementary approaches, we demonstrate that SEPT9 mRNA and protein are expressed ubiquitously, with the isoforms showing tissue-specific expression. The microarray analysis indicates that there is consistent overexpression of SEPT9 in diverse human tumours including breast, CNS, endometrium, kidney, liver, lung, lymphoid, oesophagus, ovary, pancreas, skin, soft tissue and thyroid. Since tumours are commonly associated with enhanced cell proliferation, we examined the possible correlation of Ki67 and SEPT9 expression in normal tissues and tumours. Our data indicate that the overexpression of SEPT9 in neoplasia is not simply a proliferation-associated phenomenon, despite its role in cytokinesis.

Indexed as

Gene Expression ProfilingGene Expression Regulation, NeoplasticOligonucleotide Array Sequence AnalysisCell MovementCell ProliferationGTP PhosphohydrolasesHumansImmunohistochemistryNeoplasmsReverse Transcriptase Polymerase Chain ReactionSeptinsGTP PhosphohydrolasesSEPTIN9 protein, humanSeptins

Identifiers

PMID15782116
OpenAlexW1978353502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.